Publication date: Jan 01, 2025
Data on mRNA-1273 (Moderna) vaccine effectiveness (VE) in children aged 6 months to 5 years are limited. The objectives of this study were to assess mRNA-1273 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19)-related hospitalization among children aged 6 months to 5 years during the initial 5 months of the vaccination campaign rollout, as well as to determine whether VE varied by age group (6 months to
Open Access PDF
| Concepts | Keywords |
|---|---|
| Hospitalization | children |
| Moderna | COVID-19 |
| Severe | mRNA-1273 |
| Vaccine | SARS-CoV-2 |
| test-negative study | |
| vaccination | |
| vaccine effectiveness |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 Infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| disease | MESH | Infectious Diseases |
| disease | MESH | Vaccine Preventable Diseases |
| disease | MESH | death |
| pathway | REACTOME | Reproduction |
| pathway | REACTOME | Translation |
| disease | IDO | site |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | process |
| disease | IDO | symptom |
| disease | MESH | emergency |
| disease | MESH | cancer |
| disease | MESH | influenza |
| disease | IDO | immune response |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | autoimmune diseases |
| disease | MESH | chronic conditions |
| drug | DRUGBANK | Aspartame |
| disease | IDO | production |
| disease | MESH | privacy |
Original Article
(Visited 1 times, 1 visits today)